Skip to main content
PMC home page
Frontiers in Behavioral Neuroscience logoLink to Frontiers in Behavioral Neuroscience
. 2020 Jan 21;13:287. doi: 10.3389/fnbeh.2019.00287

Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury

Jason G Thome 1, Evan L Reeder 2, Sean M Collins 2, Poornima Gopalan 2, Matthew J Robson 2,*
PMCID: PMC6985078  PMID: 32038189

Abstract

Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulates the generation and release of proinflammatory cytokines including interleukin-1α (IL-1α) and IL-1β. Both forms of IL-1 initiate signaling by binding with IL-1 receptor type 1 (IL-1R1), a receptor with a natural, endogenous antagonist dubbed IL-1 receptor antagonist (IL-1Ra). The recombinant form of IL-1Ra has gained FDA approval for inflammatory conditions such as rheumatoid arthritis, prompting interest in repurposing these pharmacotherapies for other inflammatory diseases/injury states including TBI. This review summarizes the currently available preclinical and clinical literature regarding the therapeutic potential of inhibiting IL-1-mediated signaling in the context of TBI. Additionally, we propose specific research areas that would provide a greater understanding of the role of IL-1 signaling in TBI and how these data may be beneficial for the development of IL-1-targeted therapies, ushering in the first FDA-approved pharmacotherapy for acute TBI.

Keywords: traumatic brain injury, interleukin-1, interleukin-1 receptor, cytokine, microglia, astrocyte

Introduction

Traumatic brain injury (TBI) is a significant clinical health problem. TBI is currently a leading cause of death and disability within the United States (US) (Centers for Disease Control and Prevention, 2014) translating to an annual economic cost of $76.5 billion (Centers for Disease Control and Prevention, 2019). Compounding this problem is the lack of FDA-approved treatments for acute injury, consequentially driving long-term costs due to the chronic effects of TBI. These chronic effects can include epileptogenesis, cognitive deficits, and neuropsychiatric conditions (McIntosh et al., 1996; Bombardier et al., 2010; Hart et al., 2011, 2016).

Depression is the most frequent neuropsychiatric disorder post-TBI, its incidence unrelated to degree of injury severity (Fann et al., 2013). Depression is linked to the high suicide rates following TBI, three to four times that of the general population (Fleminger, 2008; Alway et al., 2016; Ouellet et al., 2018). Cognitive deficits are inherent in TBI, including deficits in attention, working memory, and processing speed, among other issues (Cicerone, 1996; McAllister et al., 1999; McAllister et al., 2001; Chan, 2002). Post-traumatic epilepsy (PTE) is common following TBI (Fleminger, 2008), with an incidence rate between 10 and 35%, an effect positively correlated with severity of injury, and negatively correlated with age at insult (Appleton and Demellweek, 2002; Frey, 2003; Ates et al., 2006; Statler et al., 2009; Arndt et al., 2013). Management of PTE has proven difficult due to a lack of therapies for prevention/occurrence of PTE following neurotrauma (Barlow et al., 2000). It is possible that targeting acute molecular processes of TBI may prove an effective strategy for minimizing the emergence of depression, cognitive decline, and PTE post-TBI, thereby circumventing the lack of currently available treatments for these conditions.

The acute phases of TBI are characterized by profound neuroinflammation, increased glial cell reactivity, cytokine generation/release, and neural degeneration. Inflammatory cytokines, including interleukin-1α (IL-1α) and IL-1β, are the primary orchestrators of neuroinflammatory cascades, and many utilize receptors in a cell heterologous and/or autonomous fashion. The IL-1 receptor type 1 (IL-1R1) is the primary functional target of three endogenous ligands, IL-1α, IL-1β, and IL-1 receptor antagonist (IL-1Ra) (Symons et al., 1995). Upon activation, IL1-R1 recruits IL-1 receptor accessory chain protein (IL-1RAcP), also known as IL-1R3, forming a heterotrimeric complex with IL-1R1 and the bound ligand (Casadio et al., 2001). Toll/IL-1 receptor (TIR) domains within the cytoplasm form a complex with the myeloid differentiation primary response gene 88 (MYD88) adapter protein, subsequently recruiting IL-1 receptor-associated kinase 4 (IRAK4) (Burns et al., 1998; Xu et al., 2000; De Nardo et al., 2018). Once recruited, IRAK4 trans-autophosphorylates, recruiting and phosphorylating IRAK1, and forming a complex with tumor necrosis factor receptor-associated factor 6 (TRAF6) (Ye et al., 2002; Burns et al., 2003; Ferrao et al., 2014; Vollmer et al., 2017). The IRAK1/TRAF6 complex initiates phosphorylation of membrane-bound transforming growth factor beta-activated kinase 1 (TAK-1), leading to downstream activation of the transcription factors nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1) (Lee et al., 2002; Shim et al., 2005; Figure 1). Together, these transcription factors promote the production of a myriad of proinflammatory cytokines involved in neuroinflammation, including IL-6 and IL-1β (Collart et al., 1990; Sung et al., 1992; Serkkola and Hurme, 1993; Jeon et al., 2000; Roman et al., 2000).

FIGURE 1.

FIGURE 1

Open in a new tab

Various forms of neurotrauma induce interleukin-1 receptor-mediated signaling in the CNS. (A) Interleukin-1 receptor (IL-1R1) activation occurring from IL-1α or IL-1β binding in various glial cells, endothelial cells, and neuronal populations is associated with reactive gliosis, the further generation and release of inflammatory cytokines/chemokines, neurodegeneration, and ultimately, alterations in behavior. (B) Acute molecular signaling associated with IL-1R1 activation in various cell types of the CNS. Binding of IL-1α and/or IL-1β to IL-1R1 acts to increase gene transcription of several inflammatory mediators including IL-6 and a feed-forward loop increasing the expression of IL-1β through an activation of NF-κB and AP-1. Several proteins, including IL-1 receptor associated kinase-1 (IRAK1) and IL-1 receptor associated kinase 4 (IRAK4), are required for IL-1R1-mediated signaling and may provide further drug targets for pharmacotherapy development. IL-1-mediated activation of IL-1R1 is known to rapidly increase neuronal excitability and serotonin transporter (SERT)-mediated serotonin clearance, effects contributing to seizure susceptibility and despair-like behaviors, respectively. (C) Recombinant IL-1Ra (Anakinra) administration has been shown in preclinical models for neurotrauma to mitigate trauma-elicited astrogliosis, edema, and cytokine generation. Further, blockade of trauma-associated IL-1R1-mediated signaling provides cognitive-sparing effects in the Y Maze and Morris water maze behavioral assays. Given promising preclinical data and the previous FDA approval of recombinant IL-1Ra, targeting IL-1R1-mediated signaling may represent a viable avenue for the pursuit of the first FDA-approved pharmacotherapy for acute TBI. IRAK2, interleukin-1 receptor associated kinase-1; IL-1RAcP, interleukin-1 receptor accessory protein; TRAF6, tumor necrosis factor receptor associated factor 6; MAPK, mitogen-activated protein kinase; AP-1, activator protein-1; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; MyD88, myeloid differentiation primary response protein.

The regulatory role of IL-1R1 in innate immune system activation renders it an ideal candidate to block downstream effects of the IL-1 pathway. Beneficial effects in inflammatory diseases, such as rheumatoid arthritis, have led to FDA approval of the recombinant form of IL-1Ra, Anakinra. The availability of this treatment has fueled interest in IL-1R1-mediated signaling for various disease states/disorders with an inflammatory component. IL-1Ra administration in animal models of cerebral ischemia, for example, has been demonstrated to provide neuroprotective effects (Banwell et al., 2009; Becker et al., 2014; Girard et al., 2014; Clausen et al., 2016; Pradillo et al., 2017), with Anakinra advancing to clinical trials for this indication (Emsley et al., 2005; Galea et al., 2018; Smith et al., 2018). Further, recent studies have aimed to delineate the role of IL-1R1 signaling within the central nervous system (CNS) following neurotrauma using pharmacologic and genetic means. Recent studies, emerging clinical trials, and potential future directions specific to IL-1R1 signaling in the context of TBI are the primary focus of this review.

IL-1R1 Localization in the CNS

While expression of IL-1R1 is ubiquitous throughout the brain, there are regions of dense expression that provide insight to abnormal behaviors believed to be associated with IL-1R1-mediated signaling. Autoradiography labeling of IL-1α and IL-1β in the mouse brain resulted in concentrated labeling of the granule cell layer of the hippocampus, choroid plexus, and pituitary gland (Takao et al., 1990; Ban et al., 1991). These studies have been corroborated via regional in situ hybridization of IL-1R1 mRNA within the dentate region of the hippocampus, choroid plexus, and pituitary gland, as well as in the raphe nuclei (Cunningham et al., 1991, 1992).

Functional IL-1R1 expression has been demonstrated in astrocytes, microglia, neurons, and endothelial cells (Liu et al., 2019). IL-1R1 mRNA is expressed at high levels in cultured astrocytes, and radiolabeled IL-1α has been demonstrated to bind to primary astrocyte cultures (Ban et al., 1993; Tomozawa et al., 1995; Pinteaux et al., 2002), implying expression of functional IL-1R1. Further evidence of functional IL-1R1 expression in astrocytes is the release of proinflammatory factors such as IL-6 post-stimulation (Gottschall et al., 1994). IL-1R1 expression is present within microglial populations; however, expression levels are substantially lower compared to astrocytes (Pinteaux et al., 2002). IL-1R1 appears to be expressed in microglial populations in vivo, as confocal microscopy analyses have demonstrated colocalization of IL-1R1 with OX-42-labeled microglia in the spinal cord (Wang et al., 2006). Binding sites for IL-1α, presumed to be IL-1R1, have also been localized to hippocampal neurons (Takao et al., 1990; Ban et al., 1991). Finally, IL-1R1 is localized to endothelial cells within the brain with activation leading to hyperthermia and cytokine signaling (Cao et al., 2001; Liu et al., 2015). The diverse localization of IL-1R1 expression within the CNS suggests a myriad of roles in the regulation of the innate immune system following neurotrauma.

Preclinical Targeting of IL-1R1

IL-1Ra

Much of the preclinical work aimed at delineating the roles of IL-1R1-mediated signaling in neurotrauma has utilized recombinant human IL-1Ra. IL-1Ra competitively binds to IL-1R1, thereby impeding the ability of IL-1β and IL-1α to bind to and signal through the receptor. These pharmacologic studies are significant due to their potential to repurpose an already FDA-approved therapy (Anakinra or Kineret). In a rat fluid percussion injury (FPI) model, IL-1Ra administration was shown to rescue cognitive impairment as assessed in the Morris water maze (MWM) (Sanderson et al., 1999). Acute IL-1Ra administration reduces pentylenetetrazol (PTZ)-evoked seizure hypersensitivity in a pediatric model for TBI, providing evidence that IL-1R1 blockade may be a promising avenue for preventing PTE (Semple et al., 2017; Webster et al., 2017). Similarly, the effects of IL-1Ra overexpression on the effects of TBI have been explored. Transgenic mice overexpressing IL-1Ra demonstrated significantly higher neurological recovery; evaluated by neurological severity score (NSS), a task which assesses performance on motor and behavioral tasks, in a closed head injury (CHI) model of TBI (Tehranian et al., 2002).

Polytrauma is common in the context of TBI and leads to profound peripheral inflammatory responses that may exacerbate neuroinflammation. Clinically, patients with polytrauma exhibit increased mortality rates compared to TBI alone: 21.8–11.1%, respectively (Wilson and Tyburski, 2001; McDonald et al., 2016; Sun et al., 2018). Controlled cortical impact (CCI) in combination with tibial injury increases brain levels of IL-1β in mice receiving both injuries compared to those receiving only TBI (Yang et al., 2016). Additionally, FPI in combination with tibial injury corroborates these results, acutely increasing brain levels of IL-1β in mice receiving polytrauma compared to TBI-only controls (Shultz et al., 2015), an effect that may arise from increased peripheral IL-1 expression and transport across the blood–brain barrier (Banks et al., 1993; Plotkin et al., 1996; Sadowska et al., 2015). Polytrauma-induced increases in IL-1β are time dependent however as after 48 h the levels of IL-1β decrease compared to TBI-only controls (Maegele et al., 2007). Sustained inhibition of polytrauma-elicited increases in IL-1 signaling using IL-1Ra reduces cortical neutrophil infiltration, cerebral edema, and brain atrophy following a CHI weight-drop model with concomitant tibial fracture (Sun et al., 2017). It should be noted, however, that IL-1R1 administration did not mitigate behavioral deficits in the MWM, Crawley three-chamber sociability task, open field, or rotarod test (Sun et al., 2017).

The caveat of studies utilizing IL-1Ra lies in the poor ability of IL-1Ra to cross the BBB and the high doses needed to see an effect. Previous preclinical studies have found no changes with low dose, 190 mg/kg IL-1Ra, but did see effects when subjects are administered a high dose of 1900 mg/kg, administered over 7 days (Sanderson et al., 1999). The authors acknowledged that giving nearly 2 g/kg of IL-1Ra is likely to supply large colloid protein load, potentially influencing brain water volumes. Thus, shear amounts of protein could be eliciting an effect independently of IL-1R1 blockade. Pharmacokinetic assessments of IL-1Ra have indicated that brain concentrations are approximately 1% of the plasma concentration at any given time, with a maximum of 2% (Greenhalgh et al., 2010).

If the IL-1Ra therapeutic intervention is pursued, one particular area of importance will be the ability for the molecule to cross the BBB. In fact, some studies have already experimented with modification of the IL-1Ra molecule to enhance its penetration of the BBB. Researchers conducting these studies fused the cell penetrating peptide PEP-1 with IL-1Ra in order to create the novel IL-1Ra–PEP fusion protein. The results of these studies found that the novel fusion protein improved delivery of IL-1Ra due to the molecule’s increased permeability to the BBB compared to unmodified IL-1Ra under the same conditions (Zhang et al., 2017, 2018). Furthermore, modification of the protein did not alter protein function, as evidenced by a significant reduction of inflammatory markers after administration of the fusion protein (Zhang et al., 2017), as well as alleviation of BBB disruption caused by initial injury (Zhang et al., 2018). While these studies focused on treating injuries caused by ischemia–reperfusion, TBIs share many of the negative effects ameliorated by the administration of IL-1Ra–PEP, which suggests that IL-1Ra–PEP would also prove useful for treating the negative effects caused by TBIs. Additionally, since increased permeability of IL-1Ra–PEP across the BBB was shown to occur whether or not the BBB was disrupted, modification of IL-1Ra would address any issues of decreased efficacy in the unmodified therapeutic due to a decrease in permeability after amelioration of the disrupted BBB.

Genetic KO Models

The role of IL-1R1 has been investigated utilizing genetic knockout models of the receptor. Early experiments involved mice with a global IL-1R1 knockout (Chung et al., 2018). Knockout mice showed increased performance on some behavioral tests in a CHI and a CCI model compared to their WT counterparts. In a CHI model, constitutive, global elimination of IL-1R1 resulted in a normalization of TBI-induced memory deficits in hidden and visible MWM platform trials, resulting in performance comparable to that of the WT sham mice (Chung et al., 2018). In a Y-Maze study, WT CHI mice had a decrease in alternating decisions compared to their respective sham counterparts, whereas IL-1R1 KO mice performed similarly to WT sham subjects (Chung et al., 2018). No overt effects of IL-1R1 elimination alone were found in any of the behavioral paradigms (Chung et al., 2018), providing evidence that inflammatory signaling mediated by IL-1R1 is involved in spatial and working memory deficits following CHI. It should be noted that due to the constitutive nature of IL-1R1 elimination in these subjects the temporal requirements for IL-1R1-mediated signaling in driving these effects are currently unknown.

Subsequent studies have focused on the role of IL-1R1 in various cell types by utilizing a genetic restoration strategy (IL-1R1 Restore mice) (Liu et al., 2015), which is able to selectively restore the expression of IL-1R1 in a cell-specific manner. Global knockout of IL-1R1 and selective restoration to microglia revealed mitigation of IL-1-driven microglial activation following intracerebroventricular (ICV) IL-1β injections (Zhu et al., 2019). Selective deletion of IL-1R1 in microglia had no effect on this process, showing an IL-1-driven microglial activation independent of microglial IL-1R1 (Zhu et al., 2019). In mice expressing IL-1R1 only in endothelial cells, mRNA expression of microglial cytokines, including IL-1β, is increased compared to WT controls (Liu et al., 2019). In a mouse model of cerebral ischemia, pan-neuronal, and brain endothelial-specific IL-1R1 deletion showed reduced infarct volume, with endothelial elimination attenuating BBB permeability and improving neurological function (Wong et al., 2019). Elimination of IL-1R1 in cholinergic neurons also improved functional outcomes and reduced infarct size, providing evidence that specific neuronal populations may be required for IL-1R1-mediated effects within the CNS (Wong et al., 2019). Another notable feature of IL-1-mediated signaling is the ability to drive sickness behaviors. Endothelial IL-1R1 expression has been found to be both necessary and sufficient to induce IL-1-driven sickness behavior in mice (Liu et al., 2019). Combined, these data have begun elucidating the role of IL-1R1 in various cell types of the CNS; however, further experiments are needed utilizing these genetic models in conjunction with models of TBI.

IL-1β and IL-1α Neutralization

Another strategy commonly employed when targeting immunologic targets is the direct inhibition of cytokine and/or chemokines through the use of antibodies aimed at these respective immunologic signaling components. In the context of neurologic disorders, it is possible that this strategy may exert similar effects as IL-1Ra administration while circumventing the issues surrounding IL-1Ra and minimal BBB permeability. With regard to TBI specifically, preclinical attempts to neutralize the actions of IL-1β using anti-IL-1β antibodies in order to mitigate IL-1R1 binding have been made. One TBI study using the CCI model used continuous ICV-delivered anti-IL-1β via osmotic pump at a rate of 0.375 ng/h to its experimental group; treatment began at 5 min post-injury and continued for up to 14 days thereafter (Clausen et al., 2009). When measured at 1–7 days post-injury, IL-1β neutralization was found to attenuate the CCI-induced cortical and hippocampal microglial activation, as well as cortical infiltration of neutrophils and activated T cells (Clausen et al., 2009). Moreover, lesion volume and hemispheric tissue loss evaluated 18 days post-injury were further reduced by IL-1β neutralization (Clausen et al., 2009). MWM evaluation also demonstrated that IL-1β neutralization reduced the significant deficits in neurological cognitive function induced by CCI, though evaluation by the rotarod and cylinder tests showed no significant reduction in induced neurological motor deficits (Clausen et al., 2009).

While the previous study explores the effects of long-term ICV delivery of anti-IL-1β on the effects of TBI, a follow-up study conducted by the same research group delivered a single 4 μg dose of anti-IL-1β intraperitoneally, first at 30 min post-injury, and again at 7 days post-injury (Clausen et al., 2011). Although measurements at 48 h post-CCI found that anti-IL-1β attenuated the TBI-induced hemispheric edema, it did not improve post-injury memory deficits evaluated by the MWM (Clausen et al., 2011). However, up to 20 days post-injury, anti-IL-1β was found to improve visuospatial learning as evaluated by the MWM, as well as to reduce hemispheric tissue loss and to attenuate TBI-induced microglial activation (Clausen et al., 2011). Taken together, these results suggest a temporal dependence for inhibition of IL-1 signaling to attenuate certain memory-associated deficits. With regards to motor function, this study corroborates the results of the group’s previous study, finding that anti-IL-1β had no significant effect on neurological motor deficits as evaluated by the rotarod and cylinder tests (Clausen et al., 2011).

The particular method used in these studies to explore the effects of IL-1 signaling on TBI-induced deficits, nonetheless, has its limits. First, the use of anti-IL-1β antibody relies on increased permeability of the BBB for the antibody to reach the brain and exert its therapeutic effects. If the body’s initial response to the antibody is attenuation of the disrupted BBB while neuroinflammation persists, then further administration of the antibody will fail to exert the desired effect on brain inflammation. Additionally, the anti-IL-1β antibody targets specifically IL-1β; however, freely available IL-1α can still signal through IL-1R1 and exert proinflammatory effects (Brough and Denes, 2015). This unaccounted signaling could confound the results of studies exploring the relationship among IL-1 proinflammatory signaling, secondary physiological effects, and cognitive/behavioral deficits resulting from TBI.

Clinical Studies

IL-1Ra

Due to the promising results in many preclinical studies showing the potential benefits of IL-1Ra treatment post-TBI, clinical trials aimed at determining a potential benefit in heterogeneous clinical populations have been initiated (Helmy et al., 2014, 2016). To date, one clinical trial has been conducted aiming to delineate whether IL-1Ra administration may provide beneficial effects in a clinical neurotrauma cohort. Briefly, 20 patients with severe TBI were recruited within 24 h post-injury and given either IL-1Ra or placebo. Shortly after treatment, the IL-1Ra treatment group showed large increases in IL-1Ra in the brain and in blood plasma compared to the placebo group (Helmy et al., 2016). These results indicate that there is some ability for IL-1Ra to cross the BBB; however, even the infiltration of large doses may be limited.

Initial clinical trials have provided evidence that IL-1Ra treatment results in an increase of pro-inflammatory M1-type macrophages, characterized by increased GM-CSF and IL-1β cytokine levels, whereas levels of IL-4, IL-10, and MDC – the cytokines associated with anti-inflammatory M2-type macrophages – are reduced (Helmy et al., 2016). These results counter previous studies showing decreases in IL-1β levels in treated groups (Sun et al., 2017). The classical view is that M1-differentiated cells induce pro-inflammatory responses and M2 macrophages antagonize pro-inflammatory responses (Martinez and Gordon, 2014); however, this view has recently come under increased scrutiny as microglia and/or macrophages exhibit a wide range of phenotypes that may be induced through a variety of insults.

It is important to note that all data involved with this particular clinical trial are from within the first 48 h of treatment, thus the long-term effects of IL-1Ra treatment post-injury must still be studied. Current trials in stage II are reportedly investigating dose effects, and while initial studies have validated the safety profile of IL-1Ra administration post-injury, a great deal of work remains in order to fully assess IL-1Ra efficacy as a clinical therapeutic for TBI.

Discussion

Currently, it is clear that targeting components of IL-1 signaling post-injury results in favorable outcomes in preclinical rodent models. Initial clinical studies have also shown currently available therapies to be safe for use in TBI populations, but there is currently a lack of data regarding their efficacy. We posit here that further work in the preclinical and clinical arenas is warranted, as each will provide crucial information required to further the potential use of pharmacotherapies targeting IL-1-mediated signaling. We also believe that recently developed molecular tools aimed at delineating the roles of IL-1 signaling, such as IL-1R1loxP/loxP mice and IL-1R1 Restore mice, will prove useful for determining the specific cell types and timelines critical for targeting IL-1 signaling post-TBI, similar to efforts in preclinical models for ischemia (Liu et al., 2015; Robson et al., 2016; Wong et al., 2019). Although IL-1-targeted therapies have been shown to be safe in clinical populations post-injury, the temporal requirements for targeting IL-1 signaling are important, and the optimization of timing post-injury should be analyzed thoroughly for studies moving forward. Concerted efforts between clinical and preclinical researchers will certainly aid in the further development of IL-1-targeted therapies, and as evidenced by studies discussed above, they may result in the first FDA-approved pharmacotherapies for acute TBI.

Author Contributions

JT and ER contributed by selecting and summarizing the relevant studies. JT, ER, SC, PG, and MR wrote the original sections of the current manuscript. ER and PG created the figure included in the review article.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. Portions of this work were supported by a Brain and Behavior Research Foundation NARSAD YI Award (MR), a PhRMA Foundation Research Starter Grant (MR), and the University of Cincinnati.

References

  1. Alway Y., Gould K. R., Johnston L., McKenzie D., Ponsford J. (2016). A prospective examination of Axis I psychiatric disorders in the first 5 years following moderate to severe traumatic brain injury. Psychol. Med. 46 1331–1341. 10.1017/S0033291715002986 [DOI] [PubMed] [Google Scholar]
  2. Appleton R. E., Demellweek C. (2002). Post-traumatic epilepsy in children requiring inpatient rehabilitation following head injury. J. Neurol. Neurosurg. Psychiatry 72 669–672. 10.1136/jnnp.72.5.669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arndt D. H., Lerner J. T., Matsumoto J. H., Madikians A., Yudovin S., Valino H., et al. (2013). Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort. Epilepsia 54 1780–1788. 10.1111/epi.12369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ates O., Ondul S., Onal C., Buyukkiraz M., Somay H., Cayli S. R., et al. (2006). Post-traumatic early epilepsy in pediatric age group with emphasis on influential factors. Childs Nerv. Syst. 22 279–284. [DOI] [PubMed] [Google Scholar]
  5. Ban E., Milon G., Prudhomme N., Fillion G., Haour F. (1991). Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus. Neuroscience 43 21–30. 10.1016/0306-4522(91)90412-h [DOI] [PubMed] [Google Scholar]
  6. Ban E. M., Sarlieve L. L., Haour F. G. (1993). Interleukin-1 binding sites on astrocytes. Neuroscience 52 725–733. 10.1016/0306-4522(93)90421-b [DOI] [PubMed] [Google Scholar]
  7. Banks W. A., Kastin A. J., Gutierrez E. G. (1993). Interleukin-1 alpha in blood has direct access to cortical brain cells. Neurosci. Lett. 163 41–44. 10.1016/0304-3940(93)90224-9 [DOI] [PubMed] [Google Scholar]
  8. Banwell V., Sena E. S., Macleod M. R. (2009). Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 18 269–276. 10.1016/j.jstrokecerebrovasdis.2008.11.009 [DOI] [PubMed] [Google Scholar]
  9. Barlow K. M., Spowart J. J., Minns R. A. (2000). Early posttraumatic seizures in non-accidental head injury: relation to outcome. Dev. Med. Child. Neurol. 42 591–594. 10.1111/j.1469-8749.2000.tb00363.x [DOI] [PubMed] [Google Scholar]
  10. Becker K. J., Dankwa D., Lee R., Schulze J., Zierath D., Tanzi P., et al. (2014). Stroke, IL-1ra, IL1RN, infection and outcome. Neurocrit. Care 21 140–146. 10.1007/s12028-013-9899-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bombardier C. H., Fann J. R., Temkin N. R., Esselman P. C., Barber J., Dikmen S. S. (2010). Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA 303 1938–1945. 10.1001/jama.2010.599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brough D., Denes A. (2015). Interleukin-1alpha and brain inflammation. IUBMB Life 67 323–330. 10.1002/iub.1377 [DOI] [PubMed] [Google Scholar]
  13. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J. (2003). Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197 263–268. 10.1084/jem.20021790 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Burns K., Martinon F., Esslinger C., Pahl H., Schneider P., Bodmer J. L., et al. (1998). MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 273 12203–12209. 10.1074/jbc.273.20.12203 [DOI] [PubMed] [Google Scholar]
  15. Cao C., Matsumura K., Shirakawa N., Maeda M., Jikihara I., Kobayashi S., et al. (2001). Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur. J. Neurosci. 13 1781–1790. 10.1046/j.0953-816x.2001.01551.x [DOI] [PubMed] [Google Scholar]
  16. Casadio R., Frigimelica E., Bossu P., Neumann D., Martin M. U., Tagliabue A., et al. (2001). Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett. 499 65–68. 10.1016/s0014-5793(01)02515-7 [DOI] [PubMed] [Google Scholar]
  17. Centers for Disease Control and Prevention (2014). TBI Data and Statistics | Concussion | Traumatic Brain Injury | CDC Injury Center. Atlanta, GA: Centers for Disease Control and Prevention. [Google Scholar]
  18. Centers for Disease Control and Prevention (2019). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths—United States,2014. Atlanta, GA: Centers for Disease Control and Prevention. [Google Scholar]
  19. Chan R. C. (2002). Attentional deficits in patients with persisting postconcussive complaints: a general deficit or specific component deficit? J. Clin. Exp. Neuropsychol. 24 1081–1093. 10.1076/jcen.24.8.1081.8371 [DOI] [PubMed] [Google Scholar]
  20. Chung J. Y., Krapp N., Wu L., Lule S., McAllister L. M., Edmiston W. J., III, et al. (2018). Interleukin-1 receptor 1 deletion in focal and diffuse experimental traumatic brain injury in mice. J. Neurotrauma 36 370–379. 10.1089/neu.2018.5659 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cicerone K. D. (1996). Attention deficits and dual task demands after mild traumatic brain injury. Brain Inj. 10 79–89. [DOI] [PubMed] [Google Scholar]
  22. Clausen B. H., Lambertsen K. L., Dagnaes-Hansen F., Babcock A. A., von Linstow C. U., Meldgaard M., et al. (2016). Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol. 131 775–791. 10.1007/s00401-016-1541-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Clausen F., Hanell A., Bjork M., Hillered L., Mir A. K., Gram H., et al. (2009). Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur. J. Neurosci. 30 385–396. 10.1111/j.1460-9568.2009.06820.x [DOI] [PubMed] [Google Scholar]
  24. Clausen F., Hanell A., Israelsson C., Hedin J., Ebendal T., Mir A. K., et al. (2011). Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice. Eur. J. Neurosci. 34 110–123. 10.1111/j.1460-9568.2011.07723.x [DOI] [PubMed] [Google Scholar]
  25. Collart M. A., Baeuerle P., Vassalli P. (1990). Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell. Biol. 10 1498–1506. 10.1128/mcb.10.4.1498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Cunningham E. T., Jr., Wada E., Carter D. B., Tracey D. E., Battey J. F., De Souza E. B. (1991). Localization of interleukin-1 receptor messenger RNA in murine hippocampus. Endocrinology 128 2666–2668. 10.1210/endo-128-5-2666 [DOI] [PubMed] [Google Scholar]
  27. Cunningham E. T., Jr., Wada E., Carter D. B., Tracey D. E., Battey J. F., De Souza E. B. (1992). In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J. Neurosci. 12 1101–1114. 10.1523/jneurosci.12-03-01101.1992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. De Nardo D., Balka K. R., Cardona Gloria Y., Rao V. R., Latz E., Masters S. L. (2018). Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J. Biol. Chem. 293 15195–15207. 10.1074/jbc.RA118.003314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Emsley H. C., Smith C. J., Georgiou R. F., Vail A., Hopkins S. J., Rothwell N. J., et al. (2005). A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76 1366–1372. 10.1136/jnnp.2004.054882 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Fann J., Hart T., University C. (2013). of Washington model systems knowledge translation, depression after traumatic brain injury. Arch. Phys. Med. Rehabil. 94 801–802. [DOI] [PubMed] [Google Scholar]
  31. Ferrao R., Zhou H., Shan Y., Liu Q., Li Q., Shaw D. E., et al. (2014). IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly. Mol. cell 55 891–903. 10.1016/j.molcel.2014.08.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Fleminger S. (2008). Long-term psychiatric disorders after traumatic brain injury. Eur. J. Anaesthesiol. Suppl. 42 123–130. 10.1017/S0265021507003250 [DOI] [PubMed] [Google Scholar]
  33. Frey L. C. (2003). Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 44(Suppl 10), 11–17. 10.1046/j.1528-1157.44.s10.4.x [DOI] [PubMed] [Google Scholar]
  34. Galea J., Ogungbenro K., Hulme S., Patel H., Scarth S., Hoadley M., et al. (2018). Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study. J. Neurosurg. 128 515–523. 10.3171/2016.9.JNS16615 [DOI] [PubMed] [Google Scholar]
  35. Girard S., Murray K. N., Rothwell N. J., Metz G. A., Allan S. M. (2014). Long-term functional recovery and compensation after cerebral ischemia in rats. Behav. Brain Res. 270 18–28. 10.1016/j.bbr.2014.05.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Gottschall P. E., Tatsuno I., Arimura A. (1994). Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res. 637 197–203. 10.1016/0006-8993(94)91233-5 [DOI] [PubMed] [Google Scholar]
  37. Greenhalgh A. D., Galea J., Dénes A., Tyrrell P. J., Rothwell N. J. (2010). Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br. J. Pharmacol. 160 153–159. 10.1111/j.1476-5381.2010.00684.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hart T., Brenner L., Clark A. N., Bogner J. A., Novack T. A., Chervoneva I., et al. (2011). Major and minor depression after traumatic brain injury. Arch. Phys. Med. Rehabil. 92 1211–1219. 10.1016/j.apmr.2011.03.005 [DOI] [PubMed] [Google Scholar]
  39. Hart T., Fann J. R., Chervoneva I., Juengst S. B., Rosenthal J. A., Krellman J. W., et al. (2016). Prevalence, risk factors, and correlates of anxiety at 1 year after moderate to severe traumatic brain injury. Arch. Phys. Med. Rehabil. 97 701–707. 10.1016/j.apmr.2015.08.436 [DOI] [PubMed] [Google Scholar]
  40. Helmy A., Guilfoyle M. R., Carpenter K. L., Pickard J. D., Menon D. K., Hutchinson P. J. (2014). Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase ii randomized control trial. J. Cereb. Blood Flow Metab. 34 845–851. 10.1038/jcbfm.2014.23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Helmy A., Guilfoyle M. R., Carpenter K. L. H., Pickard J. D., Menon D. K., Hutchinson P. J. (2016). Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. J. Cereb. Blood Flow Metab. 36 1434–1448. 10.1177/0271678X15620204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Jeon Y. J., Han S. H., Lee Y. W., Lee M., Yang K. H., Kim H. M. (2000). Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology 48 173–183. 10.1016/s0162-3109(00)00199-5 [DOI] [PubMed] [Google Scholar]
  43. Lee S. W., Han S. I., Kim H. H., Lee Z. H. (2002). TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J. Biochem. Mol. Biol. 35 371–376. 10.5483/bmbrep.2002.35.4.371 [DOI] [PubMed] [Google Scholar]
  44. Liu X., Nemeth D. P., McKim D. B., Zhu L., DiSabato D. J., Berdysz O., et al. (2019). Cell-type-specific interleukin 1 receptor 1 signaling in the brain regulates distinct neuroimmune activities. Immunity 50 764–766. 10.1016/j.immuni.2019.02.012 [DOI] [PubMed] [Google Scholar]
  45. Liu X., Yamashita T., Chen Q., Belevych N., McKim D. B., Tarr A. J., et al. (2015). Interleukin 1 type 1 receptor restore: a genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types. J. Neurosci. 35 2860–2870. 10.1523/JNEUROSCI.3199-14.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Maegele M., Sauerland S., Bouillon B., Schafer U., Trubel H., Riess P., et al. (2007). Differential immunoresponses following experimental traumatic brain injury, bone fracture and “two-hit”-combined neurotrauma. Inflamm. Res. 56 318–323. 10.1007/s00011-007-6141-3 [DOI] [PubMed] [Google Scholar]
  47. Martinez F. O., Gordon S. (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep. 6:13. 10.12703/P6-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. McAllister T. W., Saykin A. J., Flashman L. A., Sparling M. B., Johnson S. C., Guerin S. J., et al. (1999). Brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study. Neurology 53 1300–1308. [DOI] [PubMed] [Google Scholar]
  49. McAllister T. W., Sparling M. B., Flashman L. A., Guerin S. J., Mamourian A. C., Saykin A. J. (2001). Differential working memory load effects after mild traumatic brain injury. Neuroimage 14 1004–1012. 10.1006/nimg.2001.0899 [DOI] [PubMed] [Google Scholar]
  50. McDonald S. J., Sun M., Agoston D. V., Shultz S. R. (2016). The effect of concomitant peripheral injury on traumatic brain injury pathobiology and outcome. J. Neuroinflam. 13:90. 10.1186/s12974-016-0555-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. McIntosh T. K., Smith D. H., Meaney D. F., Kotapka M. J., Gennarelli T. A., Graham D. I. (1996). Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab. Invest. 74 315–342. [PubMed] [Google Scholar]
  52. Ouellet M. C., Beaulieu-Bonneau S., Sirois M. J., Savard J., Turgeon A. F., Moore L., et al. (2018). Depression in the first year after traumatic brain injury. J. Neurotrauma 35 1620–1629. 10.1089/neu.2017.5379 [DOI] [PubMed] [Google Scholar]
  53. Pinteaux E., Parker L. C., Rothwell N. J., Luheshi G. N. (2002). Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 83 754–763. 10.1046/j.1471-4159.2002.01184.x [DOI] [PubMed] [Google Scholar]
  54. Plotkin S. R., Banks W. A., Kastin A. J. (1996). Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J. Neuroimmunol. 67 41–47. 10.1016/s0165-5728(96)00036-7 [DOI] [PubMed] [Google Scholar]
  55. Pradillo J. M., Murray K. N., Coutts G. A., Moraga A., Oroz-Gonjar F., Boutin H., et al. (2017). Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia. Brain Behav. Immun. 61 117–126. 10.1016/j.bbi.2016.11.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Robson M. J., Zhu C. B., Quinlan M. A., Botschner D. A., Baganz N. L., Lindler K. M., et al. (2016). Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1. PLoS One 11:e0150068. 10.1371/journal.pone.0150068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Roman J., Ritzenthaler J. D., Fenton M. J., Roser S., Schuyler W. (2000). Transcriptional regulation of the human interleukin 1beta gene by fibronectin: role of protein kinase C and activator protein 1 (AP-1). Cytokine 12 1581–1596. 10.1006/cyto.2000.0759 [DOI] [PubMed] [Google Scholar]
  58. Sadowska G. B., Chen X., Zhang J., Lim Y. P., Cummings E. E., Makeyev O., et al. (2015). Interleukin-1beta transfer across the blood-brain barrier in the ovine fetus. J. Cereb. Blood Flow Metab. 35 1388–1395. 10.1038/jcbfm.2015.134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Sanderson K. L., Raghupathi R., Saatman K. E., Martin D., Miller G., McIntosh T. K. (1999). Interleukin-1 receptor antagonist attenuates regional neuronal cell death and cognitive dysfunction after experimental brain injury. J. Cereb. Blood Flow Metab. 19 1118–1125. 10.1097/00004647-199910000-00008 [DOI] [PubMed] [Google Scholar]
  60. Semple B. D., O’Brien T. J., Gimlin K., Wright D. K., Kim S. E., Casillas-Espinosa P. M., et al. (2017). Interleukin-1 receptor in seizure susceptibility after traumatic injury to the pediatric brain. J. Neurosci. 37 7864–7877. 10.1523/JNEUROSCI.0982-17.2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Serkkola E., Hurme M. (1993). Synergism between protein-kinase C and cAMP-dependent pathways in the expression of the interleukin-1 beta gene is mediated via the activator-protein-1 (AP-1) enhancer activity. Eur. J. Biochem. 213 243–249. 10.1111/j.1432-1033.1993.tb17754.x [DOI] [PubMed] [Google Scholar]
  62. Shim J. H., Xiao C., Paschal A. E., Bailey S. T., Rao P., Hayden M. S., et al. (2005). TAK1, but not TAB 1 or TAB 2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19 2668–2681. 10.1101/gad.1360605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Shultz S. R., Sun M., Wright D. K., Brady R. D., Liu S., Beynon S., et al. (2015). Tibial fracture exacerbates traumatic brain injury outcomes and neuroinflammation in a novel mouse model of multitrauma. J. Cereb. Blood Flow Metab. 35 1339–1347. 10.1038/jcbfm.2015.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Smith C. J., Hulme S., Vail A., Heal C., Parry-Jones A. R., Scarth S., et al. (2018). SCIL-STROKE (Subcutaneous interleukin-1 receptor antagonist in ischemic stroke): a randomized controlled phase 2 trial. Stroke 49 1210–1216. 10.1161/STROKEAHA.118.020750 [DOI] [PubMed] [Google Scholar]
  65. Statler K. D., Scheerlinck P., Pouliot W., Hamilton M., White H. S., Dudek F. E. (2009). A potential model of pediatric posttraumatic epilepsy. Epilepsy Res. 86 221–223. 10.1016/j.eplepsyres.2009.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sun M., Brady R. D., Wright D. K., Kim H. A., Zhang S. R., Sobey C. G., et al. (2017). Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma. Brain Behav. Immun. 66 359–371. 10.1016/j.bbi.2017.08.005 [DOI] [PubMed] [Google Scholar]
  67. Sun M., McDonald S. J., Brady R. D., O’Brien T. J., Shultz S. R. (2018). The influence of immunological stressors on traumatic brain injury. Brain Behav. Immun. 69 618–628. 10.1016/j.bbi.2018.01.007 [DOI] [PubMed] [Google Scholar]
  68. Sung S. J., Walters J. A., Fu S. M. (1992). Stimulation of tumor necrosis factor alpha production in human monocytes by inhibitors of protein phosphatase 1 and 2A. J. Exp. Med. 176 897–901. 10.1084/jem.176.3.897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Symons J. A., Young P. R., Duff G. W. (1995). Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 92 1714–1718. 10.1073/pnas.92.5.1714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Takao T., Tracey D. E., Mitchell W. M., De Souza E. B. (1990). Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology 127 3070–3078. 10.1210/endo-127-6-3070 [DOI] [PubMed] [Google Scholar]
  71. Tehranian R., Andell-Jonsson S., Beni S. M., Yatsiv I., Shohami E., Bartfai T., et al. (2002). Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the Interleukin-1 receptor antagonist. J. Neurotrauma 19 939–951. 10.1089/089771502320317096 [DOI] [PubMed] [Google Scholar]
  72. Tomozawa Y., Inoue T., Satoh M. (1995). Expression of type I interleukin-1 receptor mRNA and its regulation in cultured astrocytes. Neurosci. Lett. 195 57–60. 10.1016/0304-3940(95)11781-q [DOI] [PubMed] [Google Scholar]
  73. Vollmer S., Strickson S., Zhang T., Gray N., Lee K. L., Rao V. R., et al. (2017). The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. Biochem. J. 474 2027–2038. 10.1042/BCJ20170097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Wang X. F., Huang L. D., Yu P. P., Hu J. G., Yin L., Wang L., et al. (2006). Upregulation of type I interleukin-1 receptor after traumatic spinal cord injury in adult rats. Acta Neuropathol. 111 220–228. 10.1007/s00401-005-0016-x [DOI] [PubMed] [Google Scholar]
  75. Webster K. M., Sun M., Crack P., O’Brien T. J., Shultz S. R., Semple B. D. (2017). Inflammation in epileptogenesis after traumatic brain injury. J. Neuroinflam. 14:10. 10.1186/s12974-016-0786-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Wilson R. F., Tyburski J. G. (2001). Management of patients with head injuries and multiple other trauma. Neurol. Res. 23 117–120. 10.1179/016164101101198415 [DOI] [PubMed] [Google Scholar]
  77. Wong R., Lenart N., Hill L., Toms L., Coutts G., Martinecz B., et al. (2019). Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons. Brain Behav. Immun. 76 126–138. 10.1016/j.bbi.2018.11.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J. L., et al. (2000). Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 408 111–115. 10.1038/35040600 [DOI] [PubMed] [Google Scholar]
  79. Yang L., Guo Y., Wen D., Yang L., Chen Y., Zhang G., et al. (2016). Bone fracture enhances trauma brain injury. Scand. J. Immunol. 83 26–32. 10.1111/sji.12393 [DOI] [PubMed] [Google Scholar]
  80. Ye H., Arron J. R., Lamothe B., Cirilli M., Kobayashi T., Shevde N. K., et al. (2002). Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418 443–447. 10.1038/nature00888 [DOI] [PubMed] [Google Scholar]
  81. Zhang D. D., Jin C., Zhang Y. T., Gan X. D., Zou M. J., Wang Y. Y., et al. (2018). A novel IL-1RA-PEP fusion protein alleviates blood-brain barrier disruption after ischemia-reperfusion in male rats. J. Neuroinflam. 15:16. 10.1186/s12974-018-1058-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Zhang D. D., Zou M. J., Zhang Y. T., Fu W. L., Xu T., Wang J. X., et al. (2017). A novel IL-1RA-PEP fusion protein with enhanced brain penetration ameliorates cerebral ischemia-reperfusion injury by inhibition of oxidative stress and neuroinflammation. Exp. Neurol. 297 1–13. 10.1016/j.expneurol.2017.06.012 [DOI] [PubMed] [Google Scholar]
  83. Zhu L., Liu X., Nemeth D. P., DiSabato D. J., Witcher K. G., McKim D. B., et al. (2019). Interleukin-1 causes CNS inflammatory cytokine expression via endothelia-microglia bi-cellular signaling. Brain Behav. Immun. 10.1016/j.bbi.2019.06.026 [Epub ahead print]. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Behavioral Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES